Cellectis S.A. (CLLS)
Biological Products, (No Diagnostic Substances)
Latest Price
$2.85
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
--
P/B Ratio
--
Institutional Ownership
10.1% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| B Group, Inc. | 3.28M | $10.0M | 3.27% | -- | 2026-03-31 |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 3.18M | $10.0M | 3.17% | -- | 2026-03-31 |
| Long Focus Capital Management, LLC | 2.74M | $8.0M | 2.73% | -43.7K | 2026-03-31 |
| BlackRock, Inc. | 341.5K | $1.0M | 0.34% | -42.8K | 2026-03-31 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 226.9K | -- | 0.23% | -- | 2026-03-31 |
| MORGAN STANLEY | 86.8K | -- | 0.09% | -400 | 2026-03-31 |
| LPL Financial LLC | 84.3K | -- | 0.08% | -447 | 2026-03-31 |
| CITADEL ADVISORS LLC | 44.3K | -- | 0.04% | -51.1K | 2026-03-31 |
| MARSHALL WACE, LLP | 41.1K | -- | 0.04% | -137.4K | 2026-03-31 |
| BNP PARIBAS FINANCIAL MARKETS | 41.0K | -- | 0.04% | -300 | 2026-03-31 |